bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
P/S ratio for bioMérieux S.A. (BIM.PA)
P/S ratio as of 2023: 3.23
According to bioMérieux S.A.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.23. At the end of 2022 the company had a P/S ratio of 3.22.
P/S ratio history for bioMérieux S.A. from 2005 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 3.23 |
| 2022 | 3.22 |
| 2021 | 4.38 |
| 2020 | 4.37 |
| 2019 | 3.51 |
| 2018 | 2.80 |
| 2017 | 3.82 |
| 2016 | 2.65 |
| 2015 | 2.21 |
| 2014 | 1.99 |
| 2013 | 1.90 |
| 2012 | 1.81 |
| 2011 | 1.53 |
| 2010 | 2.15 |
| 2009 | 2.63 |
| 2008 | 2.13 |
| 2007 | 2.94 |
| 2006 | 2.01 |
| 2005 | 1.77 |